                           ˿µϣ20130806գ

13.08.03-05ûи
13.08.06, ӵݽǿѧۡ
13.08.06, ӡпԺֲойũ󸱽Ĳʿѧλ㲩ʿѧλٰ
13.08.06, ӡԺNIHˡФĿ
13.08.06, Զ̡ʦѧѽԡձ˶ٻѣ
13.08.06, ʦѧ⺺ѧԺڼ˵١
13.08.06, ίһ֤¼ȪǼǧ
13.08.06, ٱʡݴѧҽѧԺԺʷ
13.08.06, ѧԺտʷרҵżԻͬ
13.08.06, ڡũҵѧ2012ȹȻѧ⡷
13.08.06, ʷĸҽѧʷ֮һ
13.08.06, ͩݽѧ
13.08.06, Ժʿ8ѧǿѧä ױԻ
13.08.06, ⶾ˾̷۾ж඾

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

ӵݽǿѧۡ

2013720ڿѧ԰ڶ̳ݽ¼

ҸղŽʱ򿴵ǽЩͼһҵע⡣
2012ȫ˿ڽֲͼɫԽǸڽ̵˿
Խ͡ͼϿйģٸŷı࣬ڽ̵
ֻ20%30%ǲֵýأ˵йڽ̵ı
ģܷܲ˵й߱ߵģܣΪйν
൱һֲԾߣϸ˵ߣֻ
ΪûнӴڽ̣ụ̂û˼޵⡣ǻ
װһ飬ûԾءʶȥ˼⡣һ
èһ˵Ųڽ̣Ų񣿲š˵è
Ҳ

˵ߣӦԾߣӦǾ˼ʶ
ѡġԹУ˵ڲеġۿ
Ѿмǧʷˡߺ֮䲻һһͬ
ص㣬񣬶Ϊϵ۲ڡǻ۵˼δ
һ˼ǿ԰۷Ϊࡣ

һǾĻֱۣͨϵǲڵġ
˵Ҵû񣬴û飬û
ҲϵǴڵġûж˹ġ¶
һλߣõһȻ˷һ飬
ƬϴһҲϵۣ˵ϵǲڵġ֤˼
Ƿǳֲڵġͨĵĸۿûɶģ۾
ͨҲճһͷ֤ûʲô˵
ģû׼ϵ۶ĸûĵֿóĽۣǷǳ
ɿġһһϵνġʦҲ
ɵģϵ۵ġʲôۡˣҪ
οʱ򣬻߳˻þ˰οϵܾˡ
Ȼһļֵǿסġ

ڶ˼ۣҲԹеġԹ
ѧ˼⣬߼Ϸã񾿾治ڡʵ
֤Щν֤ݻ߼з񶨡Ʒ
֤ⷽҾùϣѧúƯ
ϲһ³˵ϵҪֹаֹˣ
ô˵ϵܵġϵֹа񣬵ȴȥֹô˵
ϵǻġϵȲֹаҲֹаǾ˵ϵǼ
ֻġϵۼֹаֹаôΪʲôа
񣿡߼߼ϲһ⣬ϵȫܡȫ֪
ȫƵġǻϵ۵ĸȻʱûл̣ϵ۵ĸ
Թȥģϵȫܡȫ֪ȫơ߼ϲ
ϵ۵Ĵڡֲһȱݣûֹ˼ȥһа
ϵۣһܵϵۣһֻܵϵۣ˵̡ʥ
ǸϵۡȻһֱ˵ϵȫܡȫ֪ȫƣϸ
̡ʥĻ֪ϵǼаģħûɶ
˼ľԵġ

һǽҪᳫģǾǿѧۣǽڿѧ
ϵִۡѧķչΪṩݣִѧķȫ
۵Ԥ⡣һչѧѧķչ˽˵
еĵλڹ˵ĿеȻģġ
һţɡϵڹšܵأ˳£
Ϊǵѧѧǵ
̫ϵĶǣ̫ϵҲֻϵıԵϵм䶼
ǣϵֻ˰ڸϵͨͨһǵĵ
ֻһСС΢ĳλһǳƫƧĽ䡣
ѧһ۲쵽̫ϵ֮ҲںܶܶǣǺ͵Ƶ
ǡôˡ˺嫵ϵ۹ܵΪʲôҪһ
ôһǳƫƧĽͷչҪĶɵ
ǵʲôֵýĵطʲô֮αأ˽⵽
ǵģĶǣûκĵطô
ûбҪȥ˵ϵڹ򣬹ࡣ
ѧѧĹס

ڶڽѧڽ۵ġǰߣѧ
˼ߣҺҪôԴ⣬
Դ⡣ܶ˾һû˼ȥˣΪĽṹôĸӣ
ȻȻģȥҪи߼ܰƳġ˵Ȼ
ӡǰҪȽ˵ȻģǱƳ
ģǺȡġһЩѧ߾ѡźߡȻѾ
⣬رȻѡ۽⣬˵ٸӵṹ
õʲôһ裬е඼ȻȻ
ȻѡġĽṹкܶΥ
ƵģٹһЩⷽӣ۾Ƿǳ
޴ƣڽ·Ͻһ޲ŵǺ޴
˵۾ơֱǵļ׵ܲʺֱߣܶļ
Ϊ޴ɵġ˵һϵĻû
ӵģûӵϵ۸Ȼѡɶû

ǽ۵һף⡣ͬ
ʱۻһףĶرǸԳû
ʵʵಢ֮顣ڵʷϣĳֻһ˲䣬ֻ
мʷڽ̵˵ֻܹʶֻܹ
ģֻܹġôû֮ǰĵʮ
ʱڣϵǲ̫įˣԴǶĻϵ۵ļҲǿ
סġ

ڽѧġҸղ˵ѧ˽
ԴԴȻλáѧһ⣬
⣬Ǿ˵ĵµԴԵԴղǰһλѽ
ԣ¡һֱǱڽ̵ϵ۴ڵһݣû
۴ڵĻЩ¡ЩԡЩģ˵Щǿѧ
ܹ͵ģֻǴϵġѧʹĽǶȽ
⣬ǵ¡ԡҲǽġѧеоǺ
ģǽѧԵµоûģҾɿ
ģ֤Ƿǳֵġ

ĸѧĹסѧо֪ڽ
ʵһġио˼ҶĻ߸
Ẓ̌ײһֳԽУϵۡν׳Ƶ
Ƿ磬Щ˷ԺͻȻ֮ԼһӳԽңǿҵ
ڽ黳˵ڽʵһֲһѧ
һܹԴԽеŴ̼ͷϱ仯Ĵų̼Ժ
кܶ˾ͳֻþĳֲڵĶˣ˽
ͷϵͷ˶ķӦߵ˹ȥԹ
ͷûпϵֻۣǸее㲻ȥ껹ио
ҶҶҲҶϷԵһײڽ̵黳
Խϵ۾ԽϡǶȿ˵
ʵʾһ֡ԲСΪ

⼸ĿѧоǿԵóһۣϵּ
費ûбҪģǻƵġʷһ£ʱ
ѧ˹һģͣ˵ѧͷΪʲôûϵ۵
λá˹ش˵Ҫϵ۵ļ衣Ŀѧоѭһ
·ģʱϵ۵ļ衣ڵЩѧо
˵ǲҪϵ۵ļ裬ΪּǻƵģǻ
ġǲϵ۵Ĵڣϵ۲ڡ

ǵпѧĻԾͻرšʷϣ
ڣкܶĴѧߣȻ񣬵ǲ˵Լߣ˵
ǲ֪ߣġ˹̹ʱҲô˵Ҳ˵
ǲŴϵۣǲųڵĿԣǸϵһأ
ڲţԺܹ֤ϵ۴ڣš͸
һءԲ֪۾һųġСۣ
ԼҲΪڵʱĿѧоˮƽҰѻ˵
ѾôֵĿѧ֤ܹ˵Ϊϵ۴ǻģΪʲô
Ҵ󵨵˵ҾߣҲϵ۵Ĵڣϵǲ
ģ

Խڿѧϵۣǵ̬ȷǳ
ǵǳļᶨΪͨˣпɿĻģǾǿѧ
ûʲôȿѧɿġȻѧķѾ˵ڽ
ֻһֲһԲеǵȻûбҪȥţԻ
رļᶨһЩˣһЩͽ۵ʱ˵ڲ
ףԺҲһ߱ߣȥϵ۵ġһЩ
˻ͽȷʵǰǲģȥʿ̣ˡ
һ𣬾ǰߵʱǸèһģһ֪
״̬ҵǾ˼ġԾΪпɿĿѧģ
˵оٵѧɱԺĿѧչƷˣҲŻ˵ȷ
ܴڣǰˡЩѧĳɹǲܱƷģΪһЩ
ĿѧʵرѧѧѧЩ֪ʶҿǲ
ܱƷģôҾͲԺͻȻ֮һߡ
һͻȻߣͻȻˣǴҼסһԲˣǸʱ
˵Ļǲġ

˺ϲڽ̣йˣҲϲڽ̣ԭ
ΪǾ壬壬ִ
۵ļƻģȻű塣ǲϲѧѧ䲻ϲ
ۣΪΪ۰ģرе
桢ûˡ˵û壬Ҳû塣
ȷû壬ûûʲôϵû
壬塣ܶĲ֪ߣܶߣǶȹ˳
һûҪڽͷȥѰ塣е˾Ϊ
ģû壬˼ʧȥůûһϴ
šȷģСҲӦ
ů˼䡣

ЩڽͽڱţȡůϽáһĳЩ
滥֧֡ЩֵѧϰġΪͽܱȡůΪ
Ϊʲôܱȡůͬ໥֧֡໥໥Բ
ԣڿֻᣬҲǱȡůΪȥ꿪һʱ򣬲μֻ
ʮˣһٶˣԺŻԽԽ˵мˡ
ǧ˲μӣòҸĵطһ档Ҫߴ
ĻǣҲȡů

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

  пԺֲойũ󸱽Ĳʿѧλ
      㲩ʿѧλٰ

                    ӡ

йũҵѧʳƷѧԺһǡڡʿʦ㣬
Ƶýרҵ۸ʳƷƷ¼ֳǲ
װſڿӺѺ΢ϴ6㵽ڶ糿8㣬ÿӷ
һٶȣͨﵩ400΢ּ֣¼Ӽ
־ȥоģΪǲ˵ѧǷס
ȷĲʿѧλķǳֵоǳأ1994ҵڹ
ҽѧԺٴҽѧרҵ֮У5Ÿɲ2001꣩䣨1999
2002ְ人ѧ˼˼רҵһ˶ʿȻ2003
ͻȻȥйѧԺֲоʿȥˣо΢Ϸ
＼2006˳òʿѧλָʦΪ͢ԺʿͰ׿о
Ա

ΪʲôֲһרҵȥʿΪвʿ
Ȼǣ͢ΪйѧԺԺʿйֲѧ³ԴӦ
㡣Ϊֳ˾˵ѧƸ¼ãҲǣڶ֮
ǰδκֲѧ֤ⷽسЦ
ĲʿѧλĿķ֪ʹɲʿҲû
ܵǡѧѵôĽ;ͨϵߺȥġ

2007ҵȥйũҵѧʳƷѧԺ̡ҩʳʳƷıܡ
͡ͳʵơǵʦڶ꼴ΪڣȻֵ
߲ɺѧرʼʳƷ򹤳̡
ĲʿʦڴѧڵĿɲףǿʲôֱ
оƿɳ£ʵϣֱ7ΪͨѶƲԺ
J. Agric. Food Chem.һƪ֮ǰΪҪߣһ
߻ͨѶߣӢֻһƪֲĹAppl. 
Microbiol. Biotechnol.¼AMBϣ

Y. Zhu, X.B. Chen ,K.B. Wang, K.Z. Bai, T.Y. Kuang*, H.B. Ji*, 2007, 
A simple method for extracting C-phycocyanin from Spirulina platensis 
using Klebsiella pneumoniae, Appl. Microbiol. Biotechnol., 74: 244-248 
(http://link.springer.com/article/10.1007%2Fs00253-006-0636-7 )

ƪڿĵıΪѧڼҪɹ䲩ʿѧλĵ
һҳôдģ

Zhu Yi, Chen Xiaobo, Wang Kebin, Li Yongxin, Bai Kezhi, Kuang 
Tingyun*, A simple method for extracting C-phycocyanin from Spirulina 
platensis using Klebsiella pneumoniae, Appl. Microbiol. Biotechnol. 
(revised)

ʱͶ󷵻޸ĵĽ׶ΡƪAMBĵļ¼200512
26յͶ壬2006815յ޸ĸ壬930ϷǱȽϷ
ԭԲͬ

һԭȫȫĳΪд
˲⡣AMBд˹涨ʵϸÿ淢йܶȫ
й࣬ȫʶ𣬸ĳд͸ʶ𡣳Ϊ
ⱻͬƪģʵ벻ΪҪ޸ġ

ԭȣһͨѶH.B.Jiɷ򼾺
ʱ׶ʦѧڣרҵǵѧĵоݣ
ʵȡ޹ϵѧͨѶ߾ǿ⸺ˣ
֪ʶȨߣΪʲô׶ʦѧĵѧרҵȥֲ쵼
＼Ŀ⣿ţΪԭ߶ǣڷ
ȴͻȻҪͨѶߣĵ֪ʶȨҲֲתƵ׶ʦ
ѧ

֪ͬЩ仯𣿺ֻ֪֪ܿܲ㡢
򸾰ƪǵķ¼УΪҪ
ģĵͬжûƪġǺܿܵ
ڶ֪ƪѷˣΪѱĳдױˡ

ڷУ͢ҲΪͨѶߣҲе䣬Ҳ֪
֪ܿܲΪŻйģkuang_tingyun@yahoo.com.cn
͢ƵͨѶߵģĵȫֲ䣬ֻƪ
Żй䡣ʵϣŻйֻƪУ
κεطֹҲ˵Ϊ˷ƪĶصȥע
ģķͲˡô͢бҪΪ˷ƪģǰ
һֱõֲ䲻ãصȥעһȷݵҵ𣿵Ȼ
ûбҪΨһĽǣעģĿΪð
͢ڿ༭ϵ

䲩ʿѧλĵлжԿ͢Ƽͬǧлȴ
͸ɷ򼾺֪ʶȨת׶ʦѧռ
гɹ

Ĳʿѧλġ΢Ϸؼ＼
Ŀܴʵʲôؼ＼ûʲ
ôϵǲʱŨȣԼһַǳ򵥵ķȡ
סҿ˶ʿӼˣҪ˵Ϊʿ
ģֱ21͵ֲѧʿǼʹô
Ŀ⣬Ҳɣ˱ݡϮҳױ
ͼұصٺͿЦĴ

ݵĴһp.1245.5ڶеУ6
У4ı׼SDȻ0.1˵Ϊ뵼µģ
ı׼ȴֱַ0.080.01ڱ׼ֵԲͬ
Ʋȥġp.1235.3AMBĵı1չʾ
ͬһʵĽֵǣǵֵȻȴȫһ
һȡЧʵֵѧλ92.001.96AMB91.002.96
ͬһʵ飬һдѧλģһ
дڿģp.1235.4AMBĵı1ͷݣչʾҲ
ͬһʵĽѧλϵݶԼ1.21.5AMB
ϵǾȷֵ1.36ֻݴͬĻô󳦸
ݵpHδѧλϵ8.09.0AMBϵ5.72

㻹ѧλдģسϮ˵ġűĶûע
˵Ĵ󲿷־Ǵơճɡֻǰ沿ּ
ճӣ

p.2 2Σճ»롰⾭áʱ56
http://news.xinhuanet.com/fortune/2004-04/08/content_1408054.htm 
p.103Σӷ̵΢ø̵á
http://www.cnki.com.cn/Article/CJFDTotal-WSWT198503011.htm ԭ
1985꣬һɵλ˷ӡҲճ󣬶֪Ҫ
ĳɡĦȴ޹ص(׳Ǵ̨ѧ
ġ΢ΪԴ)
p.122Σp.181κͱp.2445Σp.251Σp.2612Σ
ȫճ̨ѧġ΢ΪԴ
http://ind.ntou.edu.tw/~b0232/hydrogen.htm ̨ϰ߱
ˡճ
p.263ε3俪ʼԡձ¡＼չྻԴ
(http://www.biotech.org.cn/news/news/show.php?id=20966 )4
ƪº͡ձһƪ¡＼ڷչྻԴ
http://www.bioon.com/bioindustry/bioenergy/339441.shtml ƴնɡ

ƵĳϮӲʤö٣ֻһС֣Ѻ΢@that2008 
иչʾҲֻһС֣ľδεزκ
ʹڳϮдҲǷǳ淶ģοȫճ

лһЩЦԷǵͼ磺

p.49ͼ2.7Ũ߾·˸ֵ
p.51ͼ2.8ͼı߾һ£һ20΢ףһ100΢ס
p.67ͼ3.5Ũֳֵָ
p.85ͼ4.4ͼͱȻһģıעһ1֡
p.118ͼ5.2Īسһ¶vs¶ȵĵֱֵߡ

⣬AMBͼ1ĺ꣬˹ĺСֵ仯600
700650750

㲩ʿеױǴӱ˵ֱӸƺճģ
˸ʽĸʽʹеڿȫƣеде
б壬еûãе׸ĸдеСддϣеоšںţ
еֻںţеİд©д˴롭μѺ
΢@that2008 һƪ1935ĵģp.1511985ķ
ﲩʿѧλģp.153˵ûпЩס

ıӦÿ͹ۡϽ㲩ʿȴ˴ۡѧ
ı˵дģ̿磺

p.3 ǽҵرǿйߵر
p.17 ѧĬĬڵʵҲŬ
p.29 Melis˵㿼ķʽũ
p.47 ÿһڣܵȾȻԸսʱ
ԣʱ崦״̬ȾļʼˣҲвɴ⣬޾
ʶʵĳɹҪġ
p.56 ʿ״˲ȫϸɲǼͱˡ
p.57 ӦܷʲôӦܹʲô
ܲϣḶ́Ҫøϵ˼άж
p.104 ǿһʵеļʮһεļܹ
Ӧõ⡣
p.146 ʵܶѧ󣬺ܶﱾĴл̣򵥵ش
ţѧоǽӽоıʾ̽δ֪

дѧģдɢģ

ĵʵҲǳ졣磬бëƶ
ΪжǾ뵽ҪöＤصᷢʲô
仯p.92ĪΪܴƤʼ壿򣬰ȡ
ҽʽ˼άＤءǲҲԣ

ĲʿѧλģˡɲǼͱˡҪֲ
ΪΰһûרҵûѧоʵΪʿı
ݺͳϮ㲻ѧºѧ淶Ƶʵơͼͱ
ûܹѧѵΪܹòʿѧλĲʿѧλ
ͨ䵼ʦίԱԱҪôҲûѧҪô
ûжģһѧ˶һģҲѷ
Цٳ޸ԣĲʿѧλӦñ䵼ʦ
ҲӦñ׷ǲֲĳ裬Ҳǡҵ
رǿйߵر

ͣԺѧλίԱ칫ңйѧԺѧУ״ѧλί
Աϯ·顢ѧѧλίԱϯ֣йѧԺֲо
ơѧίԱο͢ơѧλίԱƽйũҵѧУ
±ʳƷѧԺԺƲ

2013.8.6

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

           ԺNIHˡФĿ

                       ӡ

ԺNIHˡФĿԭǡо
鷽δNIDDKNIHʻ׼http://t.itc.cn/mghCq 
ФޡǰФڡϷбϴţФ
ѧڿչģǳáΨһһйѧ


ФNIHֹФٴĿΪNIHѾ϶Ф
ȫҪԭȫݡԲֽƱ͸ЩƷ
ƭ˵ġƷΪЧ̫ˣԲٴֱС
һƭˡ֪ٴҪڲ˶ЧԺͰȫԵ
ΪФФйǸҽԺĳɹʴ
85%ڼǰҽԺȤ˵һٴ12ˣ
ЧоҪģڶٴĿҪЧһ
ֻǶ԰ȫûлóʷNIDDK׼Ŀ
NIHֹˡȻоǮѾõˣʹջأҲֻܼȥ
оĻһ۲죬˽һٴ飬
겻ٴ飬ͲٴӦá

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

ʦѧѽԡձ˶ٻѣ

ߣԶ

ձ82A22濯˸ñ߶ĵ绰ɷáڶ̶
ĲɷйȻҥٴʾһƭԲĵĳª

1992֮Ͳ򣬹𣿷Ҳʵǣ
ֳ̨19982001ֳ
ġ̡ܽ⣬ġ̳2002ġ

һϰߣһҥ֡ڲɷơ
ӶҺ֮ǡʵȫǵߵڰס˿2002꿪ʼϿǽ¶
ѧ˺ѧ١ϮԡĴ칦ܵȣԡѧʦ
һʦԾӵķߺ޺˿¶½ʦ͹Աѧ
Ϊ¶ѡ͵Ҳм۵
ıع⣬ФѡɱˣѡҥʩЩ
СϣФ֣ʫ׽Фϴ
ƣԸմȾֳԶϻ죬ղԸ

ʮǰϹҲҥȣ¶
ֳµкܶ࣬ӴδдһƪӡΣЩ
ǹҲҥŵĻԼ˵˵Щӹˣ
ʲôˣĩ˿վǵĽ¶ֲ˵Ĳ£
ȤĶ߿Կ˳Ҳ˽Ǹʲôɫ

˵ԷʮĹ˵ˣҥ
Ҳѡʵϣ˿¶УĶ۵ľ
Ϊ˻ԽװƷåӼ
˿վչʮԭ򣡡˼˿Ͽһƪ¶£
10ƪҥӡ˵ҥϣܶ๥
ӵӰӣԷӼݾԴʵ
׳ġ֮һǷ˵ġǣһͶ
֪ˡ

˵ȥԺӣӣļ֡
ǸǳͷβҥѡйѧԺ
ұоǸȽϸӣɴӴĲ֪
һȣʵǳ˵ģ֮԰Ϊ
ѧٵķʽԣĽ¶ʵ֤ݣΣû߼
ҲҲдǸԭԴһ
ҥݡߵֻдһˣ˵ġ
֤֤ʵĽ¶ԸΪ뷽ûйϵģ
ȥԺ߷ӣûԺ

ڼ硰㵽û칦ܣ⣬ȡ˻رܵ
ԡаԼ˵óһ㣬ʵʱȴңĶ
ȥˣǵĴѧʲôʱ˽Сˣ

Ϊʱڶ཭ƭеһԱԺձ
һƪٳƭȡһֽʿѧλƾԴ˻½У
˽ϰԲãѧ£Ѵţҥݵȴ
˾Ȼܵʦ治ʲô

ʦԱҲйףӦǵҪ󣬴˴

˿ϵ

1 İ ŵоԺǲ綥ѧ(Դ)´ɻ 2002.11.03
2 ⲩ Ժʿס 2002.11.6
3 ⲩ ԺʿҪҶ 2002.11.11
4 ⲩ Ժʿ𸴴ɡ 2002.11.18
5  ԺʿĲʿѧλ 2002.11.19
6  ѧƭԴ֤ 2006.10.30
7 SamuelһЩû˵ 2006.11.02
8 Alex 伸Դ 2006.11.03
9 κƽİ٤Ǹʲô2006.11.04
10 zhangqunӢʱԲд2008.02.05
11 SEIKO&MAIKAI ˵"ƭԴ"𸴡 2008.06.29
12 SEIKO&MAIKAI ƭԴ"ѧ" 2008.07.07
13 SEIKO&MAIKAI йѧͼԴѧƭӣѧ 2008.07.17
14 ʦѧ ⺺ѧо͡ͼ˵ѧʷָ֮һ 2008.07.29
15 ˴ϻ ѧͼƭԭڳԼˡ 2008.07.31
16 ʦѧ ⺺ѧо͡ͼ˵ѧʷָ֮2008.07.31
17רѧͼĿĿ2008.08.01
18 ʦѧ⺺ѧо͡ͼ˵ѧʷָ֮2008.08.03
19 ʦѧһйѧͼزز2008.08.04
20 ķķ ġ롰٤һ2008.08.08
21 ˴ϻ йѧͼԴҲϴ⡷ 2008.08.08
22 ʦѧ⺺ѧо͡ͼ˵ѧʷָ֮ġ2008.08.12
23 ķķԴͨġ롰٤2008.08.13
24 ˴ϻ йѧͼåѧԴ⡷ 2008.08.13
25˴ϻơѧͼݵ޳åԴ⡷2008.08.16,
26ķķͨ󡪡ġ롰٤2008.08.25
27ķķЦšԴġ롶졷ģ2008.09.24
28 ٵ治ˡ˴ͼݵʦ˵ѡ2008.11.25
29¡˴ͼݵԴʦ1993ԷΪоԱˡ2008.12.09
30µ֪¡йѧͼݹԱʦ¼2009.01.07
31 LanUnknown йѧʦ˵һ 20090104
32 ʯ ˴ϻ ڷ̰ӡ 2009.01.12
33 HQԴ 20110106
34 ʦѧ⺺ѧԺһʦż˳ǡУעһУɣԴ 20110517
35й䡶ʦѧ⺺ѧԺ칦һ 20110523
36 abellenʦѧϺʦѧΪʲôҪһаƭӣ20120106
37ëʦѧƭԴ»ԣð䲩Ժ20120109
38ʦѧ⺺ѧԺڳϮһ20120114
39ëʦѧɽկʿð䲩Ժ֤ȷ䡷20120119
40⺺ѧ֡ڻʦ󡰹ʺѧѧƴͷˡڼļʡ20130501

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

ʦѧ⺺ѧԺڼ˵

ߣ

ڻʦѧ⺺ѧԺ⺺ϵվʦУ
ҳӣhttp://faculty.ecnu.edu.cn/s/2562/main.jspyжദ
˵٣˵

һ۸

ڡѧר֣ŵ3ġѧʷ19ǰ
ĳⱾǡͼ˵ѧʷŵ6ġйѧԭ
йѧԤѧܹеķֱ

ŵ6ġ֪¼˺׫רҲѧר

ŵ8ġͨ˵塷ѧרʲô⣬߿ɼ
̨̡̨ǧ湫˾Ϳˡ

гһѧר̣ܽǹͷоһ
Ĵαѧ֮ǡѧרֳ̡̨硱
ಿƵ硶طܽѧȵȡӦðЩ
Ҳͬʱг

ŵ12ġѧسˮע衷ǱУ
רô۪Ԫʲôȥˣ

ڶ۸Ŀ

г ġ134ƪжظ롣һһ
Ŀͷ￴ѧоָһЩ
ר£ԼڷһЩ书־ϵĶġдѧ
ЩѧԵĶŵС

ں˲УҷһƪѧʷоѶȡ85йͼ
ۡ200810ڣݳϢ֪ԭĿ
̸ʵѩӺѧʷҵѧ̸ѧʷдԭԾ
200812ڣ˵ĵ8ڡ

ڼУй֪άûƪģƺǱ壩Ϊ
࣬һѧȥͼӡƪġƺΪʲôҪ
Ŀԭйͼۡǵġ⺺ѧоͼ˵ѧʷ
ָָѧרеĶദ󣨴Ŀأ
ר󣬶ѧߵĽʧȵȡ

ĺܲˬдһƪӦ¡ʵϸ˵ⲻһ
ƪӦ£һˣ졣ΪԱָĴӲûκλӦ
෴ȴߵ£һһҹ߳Ϯԡ
ΪƪӦûʵʵѧֵԲ⵽塣
һϣгƪģֺ¶ȥƪ£ԲŴ۸
Ŀͳʱ䡣

һУгҲкܶ⣬ʱˡ

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

ίһ֤¼ȪǼǧ



˿վһӳ¼Ȫ⡣

ڻίվϣײ鵽¼ȪֲΪУ뵽⼰۰ѧ
ߺоĿִΪ2013.1-2016.12200ĿҪ
Ǻ⼰۰50»ѧߡһ֤¼ȪϾϢ̴ѧ
Ϊǧˡ

̬ѧڵļǧ˱ع⣬ûйٷĴܵ
¼ȪڵϾϢ̴ѧҲûлӦί鲿Ӧõ¼Ȫ
⡣

ǧһУܵĹעβ֪и
ToledoѧĶѧĶٷ淴ƣȷʵ
ġ

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

ٱʡݴѧҽѧԺԺʷ

ΪһͨĿйߣȻѧίѧΪ
ϳͣģѧӦ̣żȻѯ׷һ
󣬾ϸ֤ͨѶΪݴѧҽѧԺʷӡͬʱڲ
ͬ־ĿժҪȫһ£˾̾ĵ
һͶһֲͬʱ˾̾2006-2011Ⱥ3
NSFCǷ2ƪSCI½˽⼰棬
λƺڸ˲żƻԼĿò٣ʷӷ
ģм飬ųдΪڣΪ2ƪ
µĿժҪ

1. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1530-6.

Expression of multidrug resistance-related proteins p-glycoprotein, 
glutathione-s-transferases, topoisomerase-II and lung resistance 
protein in primary gastric cardiac adenocarcinoma.
Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K.

Department of Cardiothoracic Surgery, Clinical College Yangzhou 
University, Yangzhou 225001, Jiangsu Province, China. 
shihongcan@gmail.com.cn

Abstract
BACKGROUND/AIMS: Multidrug resistance (MDR) is closely correlated to 
an unfavorable prognosis in various human cancers. However, the 
clinical significance of the expression of MDR-related proteins 
p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), 
topoisomerase-II (Topo-II) and lung resistance protein (LRP) in 
primary gastric cardiac adenocarcinoma (PGCA) remains unclear. In this 
study, the total of the four kinds of MDR-related proteins mentioned 
above were detected by using immunohistochemistry and their clinical 
significance in chemoresistance were also investigated.

METHODOLOGY: This retrospective study included 69 resected specimens 
from patients with PGCA. The expression of PGP, GST-pi, Topo-II and 
LRP in formalin-fixed paraffin-embedded tissue sections was determined 
by a labelled streptavidin-biotin immunohistochemical technique, and 
the results were analyzed in correlation with clinicopathological data. 
None of these patients received chemotherapy prior to surgery.

RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and 
LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) 
were all higher than that of the normal tissues (0, 30%, 20% and 0, 
respectively, P<0.01). PGP expression in tumors that had metastasized 
was significantly more frequent than in tumors that had not 
metastasized (67.5% vs. 24.1%, P<0.01).The expression of PGP was 
closely related with clinicopathologic staging (staging 1/2 vs. 3/4, 
28.6% vs. 58.3%, P<0.05). No significant correlation was shown between 
PGP and increasing differentiated degree (40%, 42.4% and 61.5%, P>0.05). 
GST-pi expression status progressively increased with increasing 
differentiated degree (40%, 75.8% and 88.5%, P<0.05) and clinico 
pathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 83.3%, P<0.05). In 
addition, a significant positive correlation was also observed between 
GST-pi and lymphatic metastasis (with vs. without metastasis, 87.5% vs. 
58.6%, P<0.05). The expression of Topo-II was associated with 
increasing differentiated degree (33.3%, 69.7% and 80.7%, P<0.01). No 
significant differences with Topo-II expression was found in relation 
to the clinicopathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 72.9%, 
P>0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs. 
72.4%, P>0.05). Moreover, a significant difference with the expression 
of LRP was found in relation to the clinicopathologic stage (staging 
1/2 vs. 3/4, 38% vs. 66.6%, P<0.05), and lymphatic metastasis (with vs. 
without metastasis, 70.0% vs. 41.4%, P<0.05). Comparing the well, 
moderately and poorly differentiated cohort, a non-statistical 
increasing trend towards LRP expression status was noted (50.0%, 54.5% 
and 65.3%, respectively, P>0.05). Besides, the co-expression of all 
four tested MDR-related proteins also existed. The positive rates of 
co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi 
and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and 
LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0%, 26.1%, 7.24%, 
5.8%, respectively.

CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II and LRP are 
involved in multiple mechanisms of drug resistance in PGCA. Combined 
determination of PGP, GST-pi, Topo-II and LRP may be prospectively 
valuable for optimizing the chemotherapy regimes, developing high 
quality anti-cancer drugs, and further predicting the outcomes of 
those patients with PGCA.

PMID: 19102336 [PubMed C indexed for MEDLINE]

2. Cancer Invest. 2008 May;26(4):344-51.

Expression of multidrug-resistance-related proteins P-glycoprotein, 
glutathione-S-transferases, topoisomerase-II and lung resistance 
protein in primary gastric cardiac adenocarcinoma.
Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K.

Department of Cardiothoracic Surgery, Clinical College, Yangzhou 
University, Yangzhou, Jiangsu Province, China. shihongcan@gmail.com.cn

Abstract
AIM: Multidrug resistance (MDR) is closely correlated to an 
unfavorable prognosis in various human cancers. However, the clinical 
significance of the expression of MDR-related proteins p-glycoprotein 
(PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) 
and lung resistance protein (LRP) in primary gastric cardiac 
adenocarcinoma (PGCA) remains unclear. In this present study, the 
total of the four kinds of MDR-related proteins mentioned above were 
detected by using immunohistochemistry, and their clinical 
significance in chemoresistance were also investigated.

METHODS: This retrospective study included 69 resected specimens from 
patients with PGCA. The expression of PGP, GST-pi, Topo-II and LRP in 
formalin-fixed paraffin-embedded tissue sections was determined by a 
labelled streptavidin-biotin immunohistochemical technique, and the 
results were analyzed in correlation with clinicopathological data. 
None of these patients received chemotherapy prior to surgery.

RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and 
LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) 
were all higher than that of the normal tissues(0, 30%, 20% and 0, 
respectively, P < 0.01). PGP expression in tumors that had 
metastasized was significantly more frequent than in tumors that had 
not metastasized (67.5% vs 24.1%, P < 0.01). The expression of PGP was 
closely related with clinicopathologic staging (staging 1/2 vs 3/4, 
28.6% vs 58.3%, P < 0.05). No significant correlation was shown 
between PGP and increasing differentiated degree (40%, 42.4% and 61.5%, 
P > 0.05). GST-pi expression status progressively increased with 
increasing differentiated degree (40%, 75.8% and 88.5%, P < 0.05) and 
clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 83.3%, P < 0.05). 
In addition, a significant positive correlation was also observed 
between GST-pi and lymphatic metastasis (with vs. without metastasis, 
87.5% vs 58.6%, P < 0.05). The expression of Topo-II was associated 
with increasing differentiated degree (33.3%, 69.7 and 80.7%, P < 0.01). 
No significant differences with Topo-II expression were found in 
relation to the clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 
72.9%, P > 0.05) and lymphatic metastasis (with vs. without metastasis, 
65.0% vs 72.4%, P > 0.05). Moreover, a significant difference with the 
expression of LRP was found in relation to the clinicopathologic stage 
(staging 1/2 vs 3/4, 38% vs 66.6%, P < 0.05), and lymphatic metastasis 
(with vs without metastasis, 70.0% vs 41.4%, P < 0.05). Comparing the 
well, moderately and poorly differentiated cohort, a non-statistical 
increasing trend towards LRP expression status was noted (50.0%, 54.5% 
and 65.3%, respectively, P > 0.05). Besides, the co-expression of all 
four tested MDR-related proteins also existed. The positive rates of 
co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi 
and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and 
LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0, 26.1, 7.24, 5.8, 
respectively.

CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II alpha and LRP 
are involved in multiple mechanisms of drug resistance in PGCA. 
Combined determination of PGP, GST-pi, Topo-II and LRP may be 
prospectively valuable for optimizing the chemotherapy regimes, 
developing high quality anti-cancer drugs, and further predicting the 
outcomes of those patients with PGCA.

PMID: 18443954 [PubMed C indexed for MEDLINE]

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

ѧԺտʷרҵżԻͬ

߿ѧĳʵǼٴյĹ

2013ļҳںѧԺտʷרҵż
Իͬ裨ʼģһƪƷĳɰ˴Ƭţʹ
ÿŪлɳ˵飨¶ῼΪУʦд
£ѱ˵ƷðԼƷɹأĻʷרҵ
450֣ڲѧμѵרĻĿ˵450Ҳѣ
ƫѣУҲδ¼ȡ

տյʷרҵѧʷרҵĿ
ɾ޴

߿ס

߿ǹҸѧṩƽ̨˹ȻŪ٣У
顢顢Ϊҳؽٱ.

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

ڡũҵѧ2012ȹȻѧ⡷

𾴵ķ

˿վϿ725յһƪӡũҵѧ2012
ȹȻѧ⡷õǺ˲ϻΪ
ǰUU1204523Ҫ䲻40Ϊ3꣬
ӦòûΥ档شӳһ£ˡ

http://www.nsfc.gov.cn/nsfc/cen/xmzn/2013xmzn/13/11.html  ί
ں˲ҳ

ллףվԽԽá

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

ʷĸҽѧʷ֮һ

ͬ־Ҫָʾ
1967105ɽҽѧԺιʱҪ

ܣ19686£ʡˡë˼ҽҩѧܻᡱ
ͬʱˡڴҽѧӡͬ־Ҫָʾ
ӡĵһϡ߼۹ʷϡΪøλʵ
Ļ˼ҹ2050ҽѧʷȡʷѵ
ĻӰҹҽѧѧչ¾棬ֽЩ
Ҫָʾԭԭس¼ÿۣ˻
չʾжҹִҽѧʷȤĶߣ⡣Źҫ

ԭճ¡Ŷûκθġ

ԺίԱḺͬ־㱨Уͬ־Ҫָʾ

ͬ־˵ϣԺǼ⡣һ⣬ʲôҽѧ
ҽѧȻѧѧȻѧѧûйϵ
һȻѧһᶯβҽǷǣ˵
ôУҶѧ㶮Ȼѧôܷ㣿

ڶ⣬Ҫһʲôвˣҵĵһ۵㣬˲
󣬲ǹӣеľ͸ݽ󡢹ˣ˵ǲ
Уˡҵĵڶ۵㣬ǻˣˣǻİɣ
òҽˡѧѧʹûУͬ˲һ
Ǹһˣǲܻ

Ǹˣ㶮˲ðǸϹ
ˣ㶮ðҿҽԺҽûһʲôҽѧʲô
ˡҽѧ෴ı֤ҽζѧҿҪǵҽ
ñ֤ҽͲǺҽ

һ˵ϸû˿ѣҽѧѧЩñ֤ܽͨ
ġʱлͬ־˵н׶εģѧҪѧϰҪ
Сͬ־˵ȻҪǸУڻҪЩ⡣

ͬ־˵ҽǸҽǸõҽһ
˵ˣ˵Ҳڶ˵ҲΡ
ҲˣҲ˵εòԣˡһҽһˣ˵
ܣԣɽеҽ˵˲ҲҲңҲԣǾ
ˡ

ͬ־ԺίԱṤ㱨ҪָʾѧУĹȽ
áһȥڶɱεȺڣ֯Ⱥν
ȽϺãϯ˼룬Ž᲻ͬˣŸɲıȽϺáҪ
ϯָʾһùԽгɼԽҪǫ顣˳ʤʱ
ǹȥѹƣǵĵλˡǵȨ
׼Ȩˣ˵ȨǸܺõ£ѡ˽ȥ˼ͺ
׷仯ƩҸղŽôҪΪǵͻ
Ŵ󣬵ʱҪ˵ĳ˽ʹҷˣҪҿɲΡ

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

ѧ

ձ2013080505 棩

    ݽˣͩ  

    ʱ䣺610  

    ص㣺Ĵѧ

    պܸ˺λ̸̸Ҹ˳ɳ;ߵľ顣Щ鲻һ
ѧоϣѧа

 

    һҵļͥҵĳɳӰܴҳһ
ýƶļͥҵĸμѧĽڣĴѧ
ѧԺҵĸ˺ܶѧйʷоѧʱרҵ
ѧڳѧԺھѧγ̡Ҳѵ³ԴУ
ʧܸա14ʱӢšȫҶʱ뼫
ʹʶԴڼͥҵҪԡ

    Ǽһ8ֵáȥչ˼ͥصҵĸ׺
ϡ׵ȥͼͥѶ׵Ǻܴ𺳡ʱĸ
׺˶һҪľü׵ĺѧУ
ѧҵ

    ǣҲζĸ׺Ҫ޴Ĵۡҵľ˾ܹҵĸĸ
ĸͰļҾСҪǼҴѼı
ǣеĺӱѧҵĸ׶ǵδиߵҪ󣬾ܾ
ܵܵĽ顣ǳѵĻ£˾Եá
ȻҵõѧϾʱ뿿ѧͯǮȻܼѣ
ȴѧȥӦЩȡ֪֡ұѧҵϳͷأ
˵һ·ұΪΪԼҵļ߳һ
ׯ·ɹĻûǰ;ˡ

    ϾʵʹҳͼǿʶҪԼڸȥ
ǰҴδй־顣Ǽͥ쵼ߣʱ˿
δʵϾǲпģٲԼûϣˡ



    ֮ᵽЩ飬Ϊ˵֮ø
졣ʷϣ౾ӵлԻǰ̵ȴձѹ壬
Ҳкܶΰڿ˷֮ȡóɹĹ¡

    ҾһϤӡΰйѧ1911ꡪ1995
꣩2030ڵ¹ѧϰѧɹ󣬿ʼʱѧν̣
̶ļҵڶսݻĲƸ»
ѧоᵽ˹پסһλѧšлѧϰ
ʱ˿ԵĹѧɹ
󲿷ʷᡣ

    յΰֵḶ́ǳڴĥʯ˳
̻οȷľںܶ£ûʱı
Լľûʱԥߺڣʱǵľ顣
ʷᣬǷҵ߹ҵ쵼йĥ£ܹһ
ź񻷾г쵼߸ʤһ

    ڽ棬Ҿѧѧ˼ԼӦԼǼΪ
Ҫ顣ѧӦѧϰḻ֪ʶʦӦþΪǴõѧ
ϰѯĻ֯ÿԼ9Сʱѧ۰ࡣҪҵѧĶ
һЩǵĿⲢֱص£һЩǵǰѧʶ
⡣

    ֮ѧǱսЩ֮
ǻʵķԾĳЩиõ⡣Щѧͼƭ
ǵ֪Щѧͨ޷ƶѧƽ˼ľ衣
ǰοѧʵͼǽԼĴ
־鲢ѧʣ»߾Ӫҵû
սͻȱ飬ʩչŻ

    ѵĻ˱øӳ졣Ƿ˵õΪƱ
ѧߵĳɹȴкġϾѧҪһȶĻ³ɳͷչ
ȵĳɹҹ۲쵽ʷϵΰѧ֮Уٷ֮
ְҵжʷϣǿһᣬһң
ս֮࣬ҪϢܳɳ

Ŀ

    ҪΪһѧߣǱ뽨һĳԶĿꡣĿ
һǳҪҪȷ׷ĵ·ϣʹսҲ
еáұ˵ĿѧоĹסҲһ
ѧңǸ׵Ľ̵ҺܾЩ㹱׵ѧߡһ
Ϊѧй׶ޱȵĻ䡣

    Ϊһƶļͥû̫ĳ·ѧҪ̫
ǮͶ룬һȽ׵ѡ񡣵Ҫǣѧź
ΰѧۿԳǧ꣬Ӱüˡ

    Ҳ֪ѧԼΪʵãԽκҪ⣬
ֵĽͶʶѧĹߡҵڸиҵȡ
޴ĳɹаļķ˹

    ҵһķ˹42ǰŦԼѧʯϪУҵʱ
ѧоĳԡѾڼѧ˺ҪĹǶµ
ѧչ˷ܲѡҲ˵ǳϲǮȥѧڣ
ŦԼȥͶʹ˾ΪɹѾĹ˾ݣ
ٴѧоȻоΪǮȤ
ףоȻ

    ҶеʱҲйойʷ뷨ڸ׵
̵һҲΪʷӰĿĿֱȻҵһ
áҾоѧΪҶеȤҵ־ѧ
ʷǼ¼ʷڽѧҪԼҵΪ
Ҫз˼άְԱѧұʷѧҸıһ棬ұ
δ׬ȡܶǮڴѧоʱȴԵ֡ҶΰѧҸ˹
ʱ˷ĪԵɷ򣬵ǣѧϣ
񽻡ӦѡѧΪһרҵɰա

    ѧҵȤѾԶԶҵʷѧ̻Ե˼
Ҽǵõһθܵѧڳж꼶ѧϰƽ漸εʱ򡣴Ӽ
ĹƵȤĶʵԡ˵ڹϣʱ
ڣϲڴϱۡϽ߼˼άõ˷չЧӦ
֮С

    ѧҪһ裬ǶΧ
۲顣ļ裬ǿԻ߼ƵҪ
߼ʵܼ򵥡A̺BB̺CôA̺CȻ⿴Ƽ򵥣
ǽһõļǴκμʵ۵ҪѰBC
ǶһѧҵĿ顣

    Ҳ˵Լʲھѧľ۵һЩ
򵥵ļ貢ɴƵҪĽۡ1994ŵ
ѧ

    ԼʲӦھѧµľĸǵ
ʷ˹1723ꡪ1790꣩ľۡѧҽЩ˵ѧ
ӦھѧоӰ

ƷζĻ

    Ǵ¿ѧо߾̣ɹоҵӦֳоԱ
˾ʼ˵ƷζԡڵĻǱҪġΪѧĹ
Ͻ߼һ̨ͿԳе󲿷ĹõһЩ
Ȼõѧ벻õѧ֮Źؼһ̨
ȷ⣬û˼άָⲢ޼ֵ
һ£޷ԼǶȻ˽Ưõ⡣
޷жʲôҪȤ⡣

    һҪ⣺ѧηҪȵĶ

    һҪ֤ͨһϵиӵɡǿǰ
ķôܴ

    ѧҿʼоһʱҪһõĹ滮续
Ҫӻõļý顣һ棬оѧһ̬Ĺ
̡ܶʱ򣬵ݻ¼ʱǿҪıоĹ滮

    ֪ѧĿɡ̽ȻĹУᵮµĿ
⡣ȤǣµоϿĿںϡǳ
Ҵ˾ĺϲ˽ҹ˾Ļôܻܿ
һ޴ĳɹ֮˽ⶼ͸ϲĽҲһ
ѡ

    ˹̹1879ꡪ1955꣩ɹؽţ
Ͻ˹ۡѧľ޴Ծ˹̹ܹɹΪ
ľͨκͬʱѧҡˣǽҵѧ
ͬʱŲ֪ͬʶŬͬĿĿ
ѧҲá

    ڿѧѧѧǶҪй㲩֪ʶܿ
Ŀ⡣ڴѧѧϰ֪ʶȡÿѧҪ󡣺õѧУ
𣬻Ҫѧѧϰ಻֪ͬʶõĺĻѧ
Ĵ󲿷ѧѧϰ̿࣬Ҳཻѡ޲ͬѧƵĿγ̡һλ
ѵĶӣڹѧʱްѧΪһѧ
ҵһ󣬿һ൱ɹĸ߿Ƽ˾ɴ˿ɼͨŽɹĵط

    ǣ漰飬ѧǲġҪо
Ժ죬˾ʵѧϰμӼѵںδѧϰĻᡣ
Ҹ˶ԣһоѧҲͬʱоѧҵĲʿ
˽ѧǰأһҵ಩ʿõѧѧ
ʿѧλѡѧʿΪҪܹѧרҵѵ
ѧϰҾһҪǲܽѧϰһѧƱĶΪ
Լѧơ

    û㹻֪ʶۣҵʵо

 

    Ƕ֪ǵְҵоҪԡͨȡ
أԡԼΪѡǵоҪȨڶ
ܵӰأҪҪԴܲĺŶӵĸ
еȵ⡣

    оҵʱҪϣҪһֱֱ
Ҫ֪ʶĻ֮ϣؿЩ֪ʶͳɵ㡣
㹻Ĵ̣صĲϣȨⲻͬףܰյľ
Ҫµֱθõʵо
ĳԶĿꡣ

    ԭ˵֮⣬δڡʱǻΪ˶ڵ
Ŀ꣬ʧռĿꡣⷽ棬½˼ΪҪá
ҷǳлҵ̫̫ҪԼ롣ǲܷԼΪ
˶ڵ˳ʼĿꡣʹĿΪ׬ǮҲҪ
ǵṹѾչһǳӵ״̬û˿Բ˵İ
߲ȥ˶óɹ߿ƼרȨķɱҵ
ĻͬҪ

    ڿ¼ԭк֪ܶ࣬ʶȨҲҪһ
֪ʶȨܵζŹʦĳɹױȡûнѧ
Һ͹ʦԸ⻨ѶŬȥµоһ˵йҵҲ
̫μͥԱˣ˽˹˾ɼ˽Ӱࡣźǣҵ
ĴӺʧˡԭȻкܶ࣬һΪǵĺ
޴ĲƸڰݶɥʧ˶߶Ծ̵ȤǸҪǶԼ
˲ΣҵҲҲ뷨ɲȫ
ءڳxҲƵ⡣һйѧֻԼѧ
ϵѡԭй˵Ĵͳѧɹ⣬Ҫ
йѧԵķҽӴѧߺͱ༭־Уҷй
ѧԵȹءѧҲͬ⡣Щѧߣ
еԺʿֺ󣬽˵뷨ŽԼͷڲ
ǰֹֽһѧ߲ΪǳϮһЩȴЩѧߣЩ
ɽկѧ߼صӰ쵽ǧ˼ƻشĿѡԺʿѡٵȵȣ
˿áȱʶ˲ҿǵթȸǺ
ܲҵ顣쵼Դ֪ѧ߹£ȷй
ѧδһԭ֮һ

    һ˵УоŨѧաѧܷȡ
óɹȻȡоԱǷȷѡ;

    ҾһЩԾӡڼݴѧʥǸУꡣ
1980꿪ʼҴ˲о1985һ꣬15оָѧϰ
ЩΪ˷ǳɫѧҡйѧѧ뵽ݴѧʥ
УѧϰҶǣǷΪҵѧ

    һλԱѧѧϣѧϰۡҰʦһλ
ѧҹ޵¡˹ˣǼݴѧʥǸУʡѧԺ˫
ƸڡʱıѧУҲڸԭûͬݴѧ
ѧնɴѧѧϰȤĴΡڲʿ
ȡ˽չȻ޷ڱҵʱҵʵĹ

    ܶһѵİ£Ϊºʲѧһ
ƸʦȻ⣬ǼİоԼ
ǰѵ֮һ20Ŭ˻ر
ȻнˮߣȴоȤȡõĳɹλѧڼ
ʢƽڡ

    һ棬һλʥǸνʱѧѧ
оҵָ£˼ѧмҪĹ
ԼĿѡ治ҵĽ顣ҵʱܶУΪ
ڡҵѺ׶ǴļѧңҲ˵ѧż
ʥǸУΪѧһԤڵְλ
һõְλΪλúܿͿԱְλѧܾˡ
ѡնɴѧΪնɿΪǩ֤⡣ûк
ʵ֤һصĴ뿪նɴѧʵЩ
УĹúܳɫϵ¹ϵϵеĽż
ȥ˾ˣټ¿СȻܳĹ
ΪƣʧѡѧΪź

    ӱÿжѡ˵Ը
ɽȻͬĽο˷һҪսֲио
˵ǷǳҪģҪĻܴлûͳɾ͸С
ᵽǸѧоĵ׶ʱңоѾʧȥ
Ȥλѧ֮ҪźǣǵҲ
ǽȻͬġһϣλѧǰ;ǹġ

    һ棬Ҳܶˣһȴһ֮ʼ
١

    ҵָ£һλѧڱҵʱò
һĵһҵΣܵѧͬʵӡǼ
ʼ©ѧ£ȡܿ
ͳαУȤҲѧоת׷Ⱥᵳ
ֶεȥ۸ѧߡѾصӰ쵽йѧǰ;
Ա̸ýҲŶԿ˵ġɫʡбȽ
˽⡣ԭ˵֮⣬ֱΪҲںʱ
;֪ӼȵȨ۷巵أһЩ̤ʵѧxһȤֿ
⡣׷ᣬҪޱȵϣҵѧ
ѧϰǱμ;ᶨƵȥ׷Ѱ

    Ҫϸɡͬеľѹ
֪ҳҰѧԻٵһ˵Ĺǰ;

    йҳӳȴûй˼ӳɳʱѧҵ͵µĽ̻
⣬Ҫõİ£õӦеȤ

    ǰһ20˸ʿ󡣸տʼʱûע⵽
䣬ĹҲɫҼʿһͬһƪ㲻¡
һ죬йʱͻȻӵһ绰˵ڼﲻͣؼУ
׽ԺȥˡҲ˽⵽Σǳʱʢ
12ѧҵ͵ѧ飬ѧҵζѧ
ʿѧλйҳĽˡҽԺֻ
˵ѧҵ̫죬ûκѣĸûа취
˴꣬ҵһμĸףҸеʧĸ׻ʩ
ѧҵϵѹص¼º󣬹꣬ȻɱˡΪ¸е
ϧ

    Ȱҳǣڽ̵Сʱ˲֮úǶཻһЩ
ѣ֪Ȥ

    ҵѧУгΪһʦģ˹̹ν̵졤ǣҺ
һͬɳѧӰ죬Ҳѧϰʹ
һòѧʶѧûˮƽǣ˷嶼
ѧмҪĹףʱ绽ѧ״öࡣ

    ʱϺμӸĸ￪źһѧõһҹªţ
ҵоʱûرע⵽ĻԻʷֱһҴ
ϺָôһŵʱҲ֪顣һ¡
ѭ浸ءϽѧݴѧɼУһѧϰ
Σ̤ʵصѧϰڼѧƵĴˣλ
ѧĹҪöࡣ˷ҲڹѧʱȺ飬ڼ
ȡýܳĳɾͣҲĹס

    Լѧ⣬ҲһЩù˳ɳиѧ
飬ڳѧļѧߺ廪ѧУ
ȻܵĳЩȨƵԺʿżȻһĹʹҾ˷ܡ
ҰϵĹڹϵõͬõһεĳѧ𽱣
ڶ־УӱΪй½һεõ𽱵ĵ
ǰĴѧѽ˥΢Ȥ˴½ѧʮ
ҪĹֵص顣Ұƣձҵʱ
ιѧѧϵϵΣѧѧϵԵͬڵְλƸ
꣬йĳЩĹʶԺʿȴ۸ĽԸ
ڹѧϵְλϾȻڹ
ְλǺŬѧϵҪ⣬õѧ
˽ʮ֪ѧʦʦǷƶȽĵ
¹˹ӢԺʿλý˵ĳɼֵ
ء

    ԼɣʧܡᶨƵѧϰʼоĲţ

 

    ˡţ٣1642ꡪ1727꣩˵һԣұȱ˿øԶ
Ϊվھ˵ļϡǻӦע⵽Щվ֮ǰ
Щ˵ļϣκҪóɹˣѧǰΰѧϰ
վЩ˵ļϣܹȡóԽǵĳɾ͡Ҫ֪
ǵЩҲΪţǰǣſ̿
ĳɹ

    ͬˣӦڽҵ֮ǰѧϰ˽
ӪҵĻſߵƶҪϣȻǰֳ׵
в˼档˵ûѵͣÿ˶Ӧò̽
µ˼·µķֻ˲ʤһӦ֪»ڹ㷺
֪ʶ˼άڵĹӦѧӲͬԴȡ֪ʶ
ЩһֱûԵĿĿޱȵΰĿ

    ͩ 1949ڹ㶫ͷ1983ѧŵ֮Ƶķ
ȽǻѧΨһĻߡ1979ͩҪת
ѧҵϣȺ󴴽ĴѧѧпԺѧġ
㽭ѧѧĺ廪ѧѧģԵЩоĸˡ
ѧڡʶѧ־΢ּ־ࡣ

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

Ժʿ8ѧǿѧä ױԻ

86յ()̡ʦעִ֮
ϾһλˮʦŷݵϢ֡ʦ
ǵġ컨׹ձ֤ҡײƭԴˣ
רҺҪȫѧĻع飬Ӫ콡ԵĻ

ʦ

ʦֵ֣ڳΪʡͰ˾
ʮһʱ͵ӪԼͲƸգơܡ
ޱ׸ּҰݷõƬʦٶȳΪעĽ㡣

ϣ֡ȡߡƵѵ䣬˵
ЩԼǡϡȥɽץġ־ʦǽƭ
ӣαѧѧ˾ϸߵֱʾɣƿ߲ǲ
ħħʦȦﶼмݵģûж߼աŮħʦҲý
ʾڵħûʲôѶȣھУŵ±
ݵİϷ

⣬ˮʦ껽թƭﱻҲٴ빫Ұ
2009꿪ʼ ߺ㶫ȶأٰ90ೡˮᣬΪ
ŮԿƽÿˮʮȻˮ
ʦȴû㵽Լ֮֡ǣʦԺռ
Ϣ׾ٵȡԺ˿͵ΣӶƭձҴ

ϾһλѾõġʦЦԷǡԳܡͨĵ
ԡˮǰΰٲÿȡǧԪȻزǰȥ
ʱȴŷݡӰ

Ϊλг

ݹ80ȫΪ֮ġȡ ѧ
ҽԺݻᣬרҽ͡ȫ
գ𽥽Ǵֱգ᲻Ͻ̶Ȳ
ߣЩΪλԼг

ýָࡰʦı󣬶һšϵǸ߹
Ȩ潻֯硣ʦǡ뾡취ύȨԻһŻ
һҪҲ֮ͣԽʧ̰ٶ෨ԽУϣһ
·˳죬ϣٷơ˶߿˵ǡǱΪ顱

ϵΪǡݴʦҪһԭĳЩԱ˺
֪ϵǵĳɹ͸ʵ֡ʦͲ縺
ĽɫΪЩṩһõƽ̨Ӷʵָ潻


ҽҩǡͽǡһ󡣡ʦǴֻشĹе
ԡҽѧ޷⡱һȤʱԽǵ˸β
˵Ĳ˾Խšʦ롰ʦĺӰعͱ
ʾȥʦΪ岻ãΪҽҩ

зָýıǡʦߺһý༭ĿƳ
ԿѧİԸֵ߸ѧʶ칦ܣδֳܱ㹻ľ衣
һ־족д֮

ȻҲųΪĹڣֻ뿴ʦġϷǷ
紫˵һ档˵ݷ֣ǳڡδ֪̽Ϊ
սİؿ

רҺѧع

١ʦܾԼĹţ޽ӵִѧϣ
ųԼΪִѧͲ˵ġڡʦǵҡײƭר
ҪȫѧĻع飬Ӫ콡ԵĻ

»2010ĵ8οѧʾй߱ѧ
ʵıΪ3.27%ζÿ100йУ3˾߱ѧ
ʣ൱ձôŷ˵Ҫ2080ĩˮƽ

пԺԺʿαѧרҺΪѧռʦʢе
ԭѧ80%ǿäܵĿѧѵ̫٣ױԻ˵
ܶ˶ѧٿѧĸʶ壬Ҫƶ

ٶʿҲ˵ΪйձȱѧԵľΪ
ѧԵľִҵĻйҪʵִҪռѧ
˼άһѣҲкܳ·Ҫߡ

йѧԺΪԺͿѧܼٴʦС
󣬵ԭṦܵȱʧһúܵ걸
ᣬһǵľ׷

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

ⶾ˾̷۾ж඾

»£յ磨 ƈң̷ֳۡΪȵ㣬
ΪȻŵĲŨ嵰׷۱ؿⶾ˾Ⱦ
Ʒѳڵ˰йڵĶҡôⶾ˾̷۾ж඾

һ

ȻţշĹ˵Ũ嵰׷۵ģʾһ
пܴⶾ״˾ⶾء嵰׷۱һ
̷۵ȲƷá̷ۡƺ¡

йʾⶾ״˾ⶾ˾޺ģ
вⶾأֳⶾأһֶԷǳǿʣ΢
Ϳҽѧרָж֢״Ҫϵͳ֢״Ϊ
ģͫɢϰͷΡѺͼⷦȣ߻̱

ʳѧļǷⶾأֻⶾ˾δ
ⶾأ֤ʳⶾжڳ˶ԣֻ
ⶾ˾ԽȻл



ⶾ˾ⶾҪһֳ¶Ϊ
϶ȣ̫̫ȣ¶ȵڣ϶Ȼڣ϶
ʱֳܷҲܲأԻڼԣڣУֵ
.ڣ.ʱҲֳܷͲء

ⶾرȣͨڣ϶֮ȣӣڣ
϶ʱȣӣͿƻⶾء

ˣ嵰׷ڽһӹо˸£һ
áʹ嵰׷ϵĿɿڿֹ˾ƣ
вóɱԼԵãϲƷǰ
ȫġ

Ȼűʾ嵰׷۵ʱꣵ£
ֱżôʱûж棬̷۵ز
ƷѹгҪ¼йء



˵ĵǣزƷпܻⶾ˾ѿߡѿЩϸ
һ¸߶Ũˮγɵ壬ڸ¡¡Ȳ
ǿĵֿЩϸӪϸڣ϶ʱֻ裱Ӿ
ѿڣ϶ȵĸ»Сʱ

ʿӾ΢ָһͥ豸ⶾ˾
ⶾأɱⶾ˾ѿߡҪɱⶾ˾ѿߣҪڸѹ£
϶СʱС

̷лⶾ˾ѿߣҲܻᵼⶾжȣӤ
׶ٵвһӤ׶̷۵ҪȺһǵĳ
ûзȫⶾ˾ѿߵⶾжˣΪ
ǻӦñʳⶾ˾嵰׷ص̷۵
Ʒ

(XYS20130806)

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)

һΪ˰޷˿վĹ˽˿վĶ̬ؿ
˿ʼбxys@yahoogroups.com

ʼбÿ췢һ˿վ¸µϣÿµ׷һÿ
Ŀ¼ʼбĶμ롰˿֮ѡ
ʼбxys_friends@yahoogroups.com

ù䶩ġù䣬ܿ޷յ
Ƽ䣺yahoo.com, hotmail.com, gmail.com

ġ˿ʼбĵ䷢һհż

xys-subscribe@yahoogroups.com 

塢ͣ˿ʼбͣ䷢һհż

xys-unsubscribe@yahoogroups.com 

Ͷxinyusi@yahoo.comôıļͶ塣

˿(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)


